Chairman of the Board will not seek re-election

Company announcement no.15/2018

For further information please contact:
Martin Riise, Head of Investor Relations, Tel: +45 5339 2250
Camilla Lercke, Head of Media Relations, Tel: +45 5339 2384

About Chr. Hansen
Chr. Hansen is a leading global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed and plant protection. Our product innovation is based on more than 30,000 microbial strains – we like to refer to them as “good bacteria.” Our solutions enable food manufacturers to produce more with less – while also reducing the use of chemicals and other synthetic additives – which makes our products highly relevant in today’s world. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for more than 140 years. We are proud that more than 1 billion people consume products containing our natural ingredients every day.

Attachment

Annual Report 2017/18

Company announcement no.14/2018

For further information, please contact:

Head of IR
Martin Riise
Tel.: +45 5339 2250
dkmari@chr-hansen.com

IR Officer
Annika Stern
Tel.: +45 2399 2382
dkaste@chr-hansen.com

FORWARD-LOOKING STATEMENTS
This report contains forward-looking statements. Such statements are subject to risks and uncertainties, as various factors, many of which are beyond the control of Chr. Hansen Holding A/S, may cause actual developments and results to differ materially from the expectations expressed in this report.

ABOUT CHR. HANSEN
Chr. Hansen is a leading global bioscience company that develops natural ingredient solutions for the food, nutritional,
pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed and plant protection. Our product innovation is based on more than 30,000 microbial strains – we like to refer to them as “good bacteria.” Our solutions enable food manufacturers to produce more with less – while also reducing the use of chemicals and other synthetic additives – which makes our products highly relevant in today’s world. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for more than 140 years. We are proud that more than 1 billion people consume products containing our natural ingredients every day.

Attachments

UMS United Medical Systems International AG: Final Payment of Liquidation Proceeds to Shareholders

UMS United Medical Systems International AG / Key word(s): Dividend/Dividend

UMS United Medical Systems International AG: Final Payment of Liquidation Proceeds to Shareholders

12-Oct-2018 / 10:24 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


UMS United Medical Systems International AG i. L.:

Final Payment of Liquidation Proceeds to Shareholders

Hamburg, October 12, 2018. The liquidator of UMS United Medical Systems International AG i. L. (UMS, ISIN DE 0005493654 / WKN 549365) (the “Company”) has made a final payment of liquidation proceeds to the Company’s shareholders, with the consent of the Supervisory Board. An amount of EUR 0.61 will be distributed to each bearer share of no-par-value stock of the Company. The distribution will be made on October 22, 2018 by the custodian banks via Clearstream Banking AG.

Any taxes owed on the final payment at the shareholder level will be determined on the basis of the individual shareholder’s situation (e.g. whether the shares are held as part of their personal assets or as part of their business assets). The final payment is a repayment of par value.

The Company in Brief

UMS International AG is a stock corporation listed in the Prime Standard of Deutsche Börse AG. On August 14,2014, the Company sold its interest in United Medical Systems (DE), Inc. and thus sold its entire assets. The Company’s Extraordinary General Meeting on September 25, 2014 approved the transfer of assets and liabilities. The agreement was finalized on November 11, 2014. Upon completion of the transfer of assets, the company’s corporate purpose was changed to the management of its own assets.

At their annual meeting on April 27, 2015, the shareholders resolved to dissolve the company on April 30, 2015.

Contact

Christian Möller, Tel: (040) 50 01 77-00, Fax: (040) 50 01 77-77, E-Mail:

investor@umsag.com


12-Oct-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: UMS United Medical Systems International AG
Borsteler Chaussee 53
22453 Hamburg
Germany
Phone: +49 (0)40 – 500 177 – 00
Fax: +49 (0)40 – 500 177 – 77
E-mail: investor@umsag.com
Internet: www.umsag.com
ISIN: DE0005493654
WKN: 549365
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of Announcement DGAP News Service

show this

UMS United Medical Systems International AG: UMS AG reports on the liquidation period from May 1 to August 31, 2018 (final liquidation financial statements)

DGAP-News: UMS United Medical Systems International AG / Key word(s): Interim Report/Interim Report

12.10.2018 / 10:00

The issuer is solely responsible for the content of this announcement.


UMS AG reports on the liquidation period from May 1 to August 31, 2018 (final liquidation financial statements)

Hamburg, October 12, 2018. UMS United Medical Systems International AG i. L. (UMS, ISIN DE 0005493654 / WKN 549365) has reported on the liquidation period from May 1, 2018 to August 31, 2018 (final liquidation financial statements).

The Company’s final legal dispute was settled in that liquidation period, as the Company entered into a settlement agreement with the opposing party. This provided the Company with a settlement amount of EUR 355k, with the earnings per share amounting to EUR 7 cents per share. The bank balances amounted to EUR 2,733k or 63 cents per share, up from EUR 2,704k at the beginning of the liquidation period. Equity increased to EUR 2,639k or 62 cents per share, from EUR 2,343k or 55 cents per share at the beginning of the liquidation period.

The full report is available on the Company’s website at www.umsag.com

The Company in Brief

UMS International AG is a stock corporation listed in the Prime Standard of Deutsche Börse AG. On August 14,2014, the Company sold its interest in United Medical Systems (DE), Inc. and thus sold its entire assets. The Company’s Extraordinary General Meeting on September 25, 2014 approved the transfer of assets and liabilities. The agreement was finalized on November 11, 2014. Upon completion of the transfer of assets, the company’s corporate purpose was changed to the management of its own assets.

At their annual meeting on April 27, 2015, the shareholders resolved to dissolve the company on April 30, 2015.

Contact

Christian Möller, Tel: (040) 50 01 77-00, Fax: (040) 50 01 77-77, E-Mail:
investor@umsag.com


12.10.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: UMS United Medical Systems International AG
Borsteler Chaussee 53
22453 Hamburg
Germany
Phone: +49 (0)40 – 500 177 – 00
Fax: +49 (0)40 – 500 177 – 77
E-mail: investor@umsag.com
Internet: www.umsag.com
ISIN: DE0005493654
WKN: 549365
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this

Heidelberg Pharma AG: Partner Magenta Therapeutics Exercises Option To Further Develop a Target Molecule as Antibody Targeted Amanitin Conjugate

Heidelberg Pharma AG / Key word(s): Alliance

Heidelberg Pharma AG: Partner Magenta Therapeutics Exercises Option To Further Develop a Target Molecule as Antibody Targeted Amanitin Conjugate

11-Oct-2018 / 11:59 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Ad hoc announcement – Inside information pursuant to Article 17 MAR

Partner Magenta Therapeutics Exercises Option To Further Develop a Target Molecule as Antibody Targeted Amanitin Conjugate

Ladenburg, Germany, 11 October 2018 – Heidelberg Pharma AG (FSE: WL6) today announced that its partner Magenta Therapeutics (NASDAQ: MGTA), Cambridge, MA, USA, exercises its option to further develop a target molecule, and will now continue the development of an Antibody Targeted Amanitin Conjugate based on the target molecule within an exclusive licensing.

In March 2018, both companies signed an exclusive multi-target research agreement under which Magenta gained access to Heidelberg Pharma’s Amanitin toxin-linker platform technology. Proprietary antibodies generated from Magenta’s stem cell platform for up to four exclusive targets were used to generate new ATACs (“Antibody Targeted Amanitin Conjugates”) using Heidelberg Pharma’s proprietary ATAC technology.

Today, 11 October, Magenta has sent us its declaration on the exercise of its option to exclusively license the worldwide development and commercialization rights to a target molecule and the resulting product candidates. Heidelberg Pharma receives an undisclosed milestone payment in return. Furthermore, Heidelberg Pharma would be eligible to receive clinical development, regulatory and sales-related milestone payments.

+++ End of the ad hoc announcement +++


Information and Explanation of the Issuer to this News:

About Heidelberg Pharma
Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. ATAC technology is the core activity of the subsidiary Heidelberg Pharma Research GmbH.

Heidelberg Pharma AG has entered into partnerships to further develop and commercialize its clinical assets MESUPRON(R) and REDECTANE(R), while RENCAREX(R) is available for out-licensing and further development. The Company is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.

About Magenta Therapeutics
Magenta Therapeutics (NASDAQ: MGTA) is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients. Founded by internationally recognized leaders in bone marrow transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Massachusetts. Since June 2018, Magenta is listed on NASDAQ. For more information, please visit www.magentatx.com.

About Bone Marrow Transplant
Healthy bone marrow stem cells and the blood cells they create are crucial for survival, but certain diseases can affect the bone marrow, interfering with its ability to function properly. A bone marrow transplant is a process to replace unhealthy bone marrow with healthy bone marrow stem cells. Bone marrow transplant can save the lives of patients with blood cancers and genetic diseases and is a potential cure for patients with severe refractory autoimmune diseases. However, the high risks, toxic side effects and complexity of the procedure currently prevent many patients from being able to benefit.

Contact
Heidelberg Pharma AG
Sylvia Wimmer
Tel.: +49 89 41 31 38-29
Email: investors[at]hdpharma.com
Schriesheimer Str. 101, 68526 Ladenburg
IR/PR support
MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89 210 228-40
Email: katja.arnold[at]mc-services.eu
 

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as ‘estimates’, ‘believes’, ‘expects’, ‘may’, ‘will’ ‘should’ ‘future’, ‘potential’ or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.


11-Oct-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Heidelberg Pharma AG
Schriesheimer Str. 101
68526 Ladenburg
Germany
Phone: +49 (0)89 41 31 38 – 0
Fax: +49 (0)89 41 31 38 – 99
E-mail: investors@hdpharma.com
Internet: www.heidelberg-pharma.com
ISIN: DE000A11QVV0
WKN: A11QVV
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange

 
End of Announcement DGAP News Service

show this